Application research of TCT DNA quantification combined with Ki67 P16 immunohistochemistry in screening cervical cancer and precancerous diseases

Zhouqing Guo,Guanghui Chen,Youming Wu,Hongxia Wang,Heguo Mo,Wencheng Deng,Na Li
DOI: https://doi.org/10.3760/cma.j.issn.1007-1245.2015.02.011
2015-01-01
Abstract:Objective To evaluate the application value of thinprep cytologic test (TCT) combined with DNA quantitative analysis and immunohistochemistry (Ki67,P16) in screening cervical intraepithelial neoplasia.Methods Women participating in cervical premalignant screening received TCT,DNA quantitative analysis and immunohistochemistry (Ki67,P16),then made methodological evaluation and clinical application value discussion.Results The positive rate of TCT screening was 11.63%,sensitivity and specificity were 81.28% and 27.50% respectively.The positive rate of DNA quantitative analysis screening was 11.87%,sensitivity and specificity were 89.83% and 19.51% respectively.The positive rate of TCT combined with DNA quantitative analysis screening was 13.54%,sensitivity and specificity were 94.11% and 15.36% respectively.The positive expression rate of immunohistochemistry (Ki67,P16) were 84% and 56%respectively,with statistically significant difference (P < 0.05).Conclusion The combination ofTCT,DNA quantitative analysis and immunohistochemistry (Ki67,P 16) can not only improve positive rate,sensitivity,specificity of screening,but also show more about the prognosis and turnover of cervical cancer and each precancerous stage,which is conducive to early diagnosis and early treatment.
What problem does this paper attempt to address?